

Supplementary Information:


Substituent Effects on Fluoride Binding by Lanthanide Complexes of DOTA-tetraamides

Octavia A. Blackburn,^a Jack D. Routledge,^a Laura B. Jennings,^a Nick H. Rees,^a Alan M. Kenwright,^b Paul D. Beer, and Stephen Faulkner^a

1	Materials and Methods	1
1.1	Synthesis of Compounds	1
2	NMR Studies	7
3	Titration data	14
3.1	Luminescence titrations	14
3.2	NMR titrations	17
4	lnK vs. D1	20
5	Rates of Exchange	20
5.1	LuL _x ¹ H NMR spectra	20
5.2	¹ H/ ¹⁹ F Inversion recovery data	22

1 Materials and Methods

1.1 Synthesis of Compounds



Scheme S1. Synthesis of benzyl-substituted ligands and complexes.

Commercially available reagents and solvents were used without further purification. Compounds **9**,¹ **10**,² **11**,³ **12**,⁴ **L**¹,⁵ **L**²,⁶ **L**³,⁷ **L**⁴,⁸ **L**⁶,⁹ were synthesised by literature procedures. All complexes were isolated as their trifluoromethanesulfonate salts.

NMR spectra were recorded on a Bruker Avance III HD nanobay 400MHz NMR with EXSY spectra and VT on a Bruker Avance III 500MHz NMR at 298 K unless expressed otherwise. All coupling constants are quotes in Hz. Abbreviations when quoting NMR data are as follows: singlet (s), doublet (d), triplet (t), multiplet (m), doublet of doublet of doublets (ddd), broad (br). Mass spectra were obtained using either an Aligent Technology 1260 Infinity or a Waters LCT Premier XS. Luminescence measurements were obtained using a HORIBA FluoroLog3 fluorimeter. All data fitting was done in Dynafit.⁹

2,2',2'',2'''-(1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetrayl)tetrakis(*N*-(4-methoxybenzyl)acetamide) (L⁵) Cyclen (0.12 g, 0.70 mmol), **10** (0.60 g, 2.81 mmol) and triethylamine (0.49 mL, 3.51 mmol) were dissolved in dry tetrahydrofuran (50 mL). The mixture was heated at 70°C for 48 h. The resultant solid was filtered off, washed with water and ethanol, and recrystallized from acetonitrile and chloroform (1:1, v/v) to give a white solid (0.15 g, 24%). *m/z* (ES⁺): 452 [M+Na+H]²⁺, 441 [M+2H]²⁺. NMR (400 MHz, CDCl₃) δ_{H} (ppm) 2.44 (s, 16H, ring CH₂), 2.89 (s, 8H, CH₂CO), 3.76 (s, 12H, OCH₃), 4.25 (s, 8H, CH₂NH), 6.84 (d, *J* = 8.7, 8H, Ar), 7.06 (t, 4H, NH), 7.11 (d, *J* = 8.6, 8H Ar). Anal. Calcd (%) for C₄₈H₆₄N₈O₈: C, 65.43; H, 7.32; N, 12.72. Found: C, 65.37; H, 7.36; N, 12.53.

2,2',2'',2'''-(1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetrayl)tetrakis(*N*-(4-fluorobenzyl)acetamide) (L⁷) Cyclen (0.20 g, 1.18 mmol), **12** (1.00 g, 4.97 mmol) and triethylamine (1.4 mL, 10.0 mmol) in DMF (50 mL) were heated overnight at 85 °C. Water (170 mL) was added and the solution was heated at 100 °C for 30 min. After cooling, the beige precipitate was filtered, washed with H₂O (30 mL) and dried. The solid was suspended in DMF (12 mL) and water (8 mL) and the mixture heated at 100 °C for 30 min. After cooling, the solid was filtered and dried to give a beige solid (0.26 g, 27 %). *m/z* (ES⁺): 833.4 [M + H]⁺. HR-ESMS found *m/z* 833.41235, calculated *m/z* 833.41204 for [C₄₄H₅₃O₄N₈F₄]⁺. NMR (400 MHz, DMSO-*d*₆) δ_{H} (ppm) 8.46 (t, *J* = 6.1, 4H, NH), 7.25 - 7.22 (m, 8H, Ar), 7.11 - 7.07 (m, 8H, Ar), 4.22 (d, *J* = 5.9, 8H, NCH₂CO), 2.97 (s, 8H, NCH₂Ar), 2.52 (s, 16H, NCH₂). NMR (376 MHz, DMSO-*d*₆) δ_{F} {¹H} (ppm) 116.7. δ_{C} 170.3, 161.1 (d, ¹J_{CF} = 242.2 Hz, C), 135.7 (d, ⁴J_{CF} = 3.2 Hz, C), 129.1 (d, ³J_{CF} = 8.1 Hz, CH), 114.9 (d, ²J_{CF} = 21.1 Hz, CH), 57.8,

53.6, 41.1 ppm. Found: C, 63.34; H, 6.27; N, 13.34. Calc. for $C_{44}H_{52}F_4N_8O_4$: C, 63.45; H, 6.29; N, 13.45 %.

Ytterbium (III) 2,2',2'',2'''-(1,4,7,10-tetraazacyclododecane-1,4,7,10-tetrayl)tetrakis(*N*-benzylacetamide) (YbL⁴) L⁴ (0.10 g, 0.13 mmol) and Yb(OTf)₃ (0.10 g, 0.13 mmol) were dissolved in acetonitrile (10 mL). The mixture was heated to 60°C for 2 d. Any unreacted ligand was filtered off and the remaining solution was concentrated *in vacuo*. Dichloromethane was added until a precipitate formed and the mixture was cooled to 5°C for 18 h. The precipitate was filtered off, yielding a white solid (0.047 g, 40%). *m/z* (ES⁺): 311 [M–3OTf]³⁺. NMR (400 MHz, D₂O) δ_H (ppm) 98.95, 18.25, 15.22, 4.55, 3.60, 3.06, 2.40, 0.02, -4.48, -26.79, -32.49, -62.13. Anal. Calcd (%) for $C_{47}H_{56}F_9N_8O_{13}S_3Yb$: C, 40.87; H, 4.09; N, 8.11. Found: C, 40.54; H, 3.91; N, 8.02.

Europium (III) 2,2',2'',2'''-(1,4,7,10-tetraazacyclododecane-1,4,7,10-tetrayl)tetrakis(*N*-benzylacetamide) (EuL⁴) This compound was prepared in a manner identical to YbL⁴ using L⁴ (0.08 g, 0.011 mmol) and Eu(OTf)₃ (0.06 g, 0.011 mmol) in acetonitrile (10 mL) to yield a white solid (0.08 g, 79%). *m/z* (ES⁺): 1211 [M–OTf]⁺, 531 [M–2OTf]²⁺. NMR (400 MHz, D₂O) δ_H (ppm) 26.73, 6.31, 6.11, 3.02, 2.35, -2.53, -6.39, -7.95, -13.40, -13.93. Anal. Calcd (%) for $C_{47}H_{56}F_9N_8O_{13}S_3Eu$: C, 41.50; H, 4.15; N, 8.24. Found: C, 41.56; H, 4.07; N, 8.19.

Yttrium (III) 2,2',2'',2'''-(1,4,7,10-tetraazacyclododecane-1,4,7,10-tetrayl)tetrakis(*N*-benzylacetamide) (YL⁴) This compound was prepared in a manner identical to YbL⁴ using L⁴ (0.08 g, 0.011 mmol) and Y(OTf)₃ (0.06 g, 0.011 mmol) in acetonitrile (10 mL) to yield a white solid (0.06 g, 68%). *m/z* (ES⁺): 498 [M–2OTf]²⁺. NMR (400 MHz, D₂O) δ_H (ppm) 1.96–2.44 (16H, m, ring NCH₂), 2.85–3.14 (8H, m, CH₂CO), 4.40 (8H, t, CH₂NH), 7.34 (20H, s, Ar). Anal. Calcd (%) for $C_{47}H_{56}F_9N_8O_{13}S_3Y$: C, 43.52; H, 4.35; N, 8.64. Found: C, 43.23; H, 4.76; N, 8.57.

Lutetium (III) 2,2',2'',2'''-(1,4,7,10-tetraazacyclododecane-1,4,7,10-tetrayl)tetrakis(*N*-benzylacetamide) (LuL⁴) This compound was made in a manner identical to YbL⁴ with L⁴ (0.10 g, 0.13 mmol), Lu(OTf)₃ (0.081 g, 0.13 mmol) in acetonitrile (10 mL) to give a white solid (0.097 g 53%). *m/z*: 1233 [M–OTf]⁺, 542

[M-OTf]²⁺, NMR (400MHz, D₂O) δ_{H} (ppm) 1.86-2.56 (16H, m, ring NCH₂), 2.85-3.20 (8H, m, CH₂CO), 4.41 (8H, s, CH₂NH), 7.35 (20H, m, Ar).

Ytterbium (III) 2,2',2'',2'''-(1,4,7,10-tetraazacyclododecane-1,4,7,10-tetrayl)tetrakis(N-(4-methoxybenzyl)acetamide) (YbL⁵) The was prepared in a manner identical to YbL⁴ using L⁵ (0.05 g, 0.056 mmol) and Yb(OTf)₃ (0.04 g, 0.056 mmol) dissolved in acetonitrile (10 mL). This yielded a white solid (0.06 g, 65%). *m/z*: 458 [M-2OTf+Na]³⁺. NMR (400 MHz, D₂O) δ_{H} (ppm) 97.82, 18.32, 15.60, 5.83, 4.70, 3.48, 2.05, 1.10, -1.07, -4.46, -26.09, -31.64, -60.58. Anal. Calcd (%) for C₅₁H₆₄F₉N₈O₁₇S₃Yb: C, 40.80; H, 4.30; N, 7.46. Found: C, 39.72; H, 4.04; N, 7.72.

Europium (III) 2,2',2'',2'''-(1,4,7,10-tetraazacyclododecane-1,4,7,10-tetrayl)tetrakis(N-(4-methoxybenzyl)acetamide) (EuL⁵) The compound was prepared in a manner identical to YbL⁴ using L⁴ (0.05 g, 0.06 mmol) and Eu(OTf)₃ (0.03 g, 0.06 mmol) dissolved in acetonitrile (10 mL) to yield a white solid (0.02 g, 34%). *m/z*: 591[M-2OTf]²⁺. NMR (400 MHz, D₂O) δ (ppm) 26.29, 6.61, 6.10, 3.48, 3.21, 2.75, 2.24, 1.10, 0.33, -2.61, -6.10, -7.88, -12.79, -13.62. Anal. Calcd for C₅₁H₆₄F₉N₈O₁₇S₃Eu: C, 41.38; H, 4.36; N, 7.57. Found: C, 41.38; H, 4.13; N, 7.97.

Yttrium (III) 2,2',2'',2'''-(1,4,7,10-tetraazacyclododecane-1,4,7,10-tetrayl)tetrakis(N-(4-methoxybenzyl)acetamide) (YL⁵) The compound was prepared in a manner identical to YbL⁴ using L⁵ (0.05 g, 0.06 mmol) and Y(OTf)₃ (0.03 g, 0.06 mmol) in acetonitrile (10 mL) to yield a white solid (0.07 g, 85%). NMR (400 MHz, D₂O) δ_{H} (ppm) 2.07-2.52 (m, ring, 16H, NCH₂), 3.01-3.22 8H, CH₂CO), 4.32 (t, 8H, CH₂NH), 6.86 (d, *J* = 1.2, 8H, Ar), 7.30 (d, *J* = 1.2, 8H, Ar). Anal. Calcd (%) for C₅₁H₆₄F₉N₈O₁₇S₃Y: C, 43.22; H, 4.55; N, 7.61. Found: C, 44.47; H, 3.97; N, 8.15.

Ytterbium (III) 2,2',2'',2'''-(1,4,7,10-tetraazacyclododecane-1,4,7,10-tetrayl)tetrakis(N-(4-nitrobenzyl)acetamide) (YbL⁶) The compound was prepared in a manner identical to YbL⁴ using L⁶ (0.051 g, 0.061 mmol) and Yb(OTf)₃ (0.038 g, 0.061 mmol) dissolved in acetonitrile (5 mL) to yield a yellow solid (0.054 g, 61%). *m/z* (ES⁺): 1412 [M-OTf]⁺, 631 [M-2OTf]²⁺. NMR (400 MHz, D₂O) δ_{H} (ppm) 88.45, 16.59, 13.81 (7.01, .031, -3.28), -23.21, -28.37, -52.72. Anal. Calcd (%) for

C₄₇H₅₂F₉N₁₂O₂₁S₃Yb: C, 36.25; H, 3.11; N, 10.98. Found: C, 36.18; H, 3.16; N, 10.66.

Europium (III) 2,2',2'',2'''-(1,4,7,10-tetraazacyclododecane-1,4,7,10-tetrayl)tetrakis(N-(4-nitrobenzyl)acetamide) (EuL⁶) This compound was prepared in a manner identical to YbL⁴ using L⁶ (0.051 g, 0.061 mmol) and Eu(OTf)₃ (0.036 g, 0.061 mmol) in acetonitrile (5 mL) to yield a white solid (0.051 g, 59%). *m/z* (ES⁺): 1391 [M-OTf]⁺, 621 [M-2OTf]²⁺. NMR (400 MHz, D₂O) δ_{H} (ppm) 23.95, 7.79, 3.40, 2.86, -3.00, -5.23, -8.43, -10.68, -12.78. Anal. Calcd (%) for C₄₇H₅₂F₉N₁₂O₂₁S₃Eu: C, 36.75; H, 3.15; N, 10.94. Found: C, 36.88; H, 3.26; N, 10.84.

Yttrium (III) 2,2',2'',2'''-(1,4,7,10-tetraazacyclododecane-1,4,7,10-tetrayl)tetrakis(N-(4-nitrobenzyl)acetamide) (YbL⁶) This compound was prepared in a manner identical to YbL⁴ using L⁶ (0.045 g, 0.053 mmol) and Y(OTf)₃ (0.029 g, 0.053 mmol) dissolved in acetonitrile (5 mL) to yield a white solid (0.048 g, 65%). *m/z* (ES⁺): 589 [M-2OTf]²⁺. NMR (400 MHz, D₂O) δ_{H} (ppm) 2.09-2.65 (16H, m, ring NCH₂), 3.18-3.32 (8H, m, CH₂CO), 4.47-4.60 (8H, t, CH₂NH), 7.53 (8H, d, *J* = 8.6, Ar), 8.14 (8H, d, *J* = 8.7, Ar) Anal. Calcd (%) for C₄₇H₅₂F₉N₁₂O₂₁S₃Y: C, 38.22; H, 3.55; N, 11.36 Found: C, 38.06; H, 3.79; N, 11.28.

Ytterbium 2,2',2'',2'''-(1,4,7,10-tetraazacyclododecane-1,4,7,10-tetrayl)tetrakis(N-(4-fluorobenzyl)acetamide) (YbL⁷) This compound was prepared in a manner identical to YbL⁴ using L⁷ (0.051 g, 0.061 mmol) and Yb(OTf)₃ (0.038 g, 0.061 mmol) dissolved in acetonitrile (5 mL) to yield a white solid (0.054 g, 61%). NMR (400 MHz, D₂O) δ_{H} (ppm) 95.0, 17.6, 14.7, 4.6, 3.7, -0.2, -4.2, -25.5, -31.0, -59.1. NMR (376 MHz, DMSO-*d*₆) δ_{F} {¹H} (ppm) -118.6. *m/z* (ES⁺): 577.7 [M-2OTf]²⁺. HR-ESMS found *m/z* 1302.24866, calculated *m/z* 1302.24464 for [C₄₆H₅₂O₁₀N₈F₁₀S₂Yb]⁺. Anal. Calcd (%) for C₄₇H₅₂YbF₁₃N₈O₁₃S₃: C, 38.85; H, 3.61; N, 7.71. Found: C, 38.66; H, 3.52; N, 7.62.

Europium (III) 2,2',2'',2'''-(1,4,7,10-tetraazacyclododecane-1,4,7,10-tetrayl)tetrakis(N-(4-fluorobenzyl)acetamide) (EuL⁷) This compound was prepared in a manner identical to YbL⁴ using L⁷ (0.051 g, 0.061 mmol) and Eu(OTf)₃ (0.036 g, 0.061 mmol) dissolved in acetonitrile (5 mL) to yield a white solid (0.051 g, 59%).

NMR (400 MHz, D₂O) δ_{H} (ppm) 25.9, 6.7, 6.3, 3.7, 3.1, 2.5, -2.6, -6.0, -8.0, -12.5, -13.4. NMR (376 MHz, DMSO-*d*₆) δ_{F} {¹H} (ppm) -115.9. *m/z* (ES⁺): 567.3 for [M-2OTf]²⁺. HR-ESMS found *m/z* 328.44150, calculated *m/z* 328.44145 for [C₄₄H₅₂O₄N₈EuF₄]³⁺. Anal. Calcd (%) for C₄₇H₅₂EuF₁₃N₈O₁₃S₃: C, 39.42; H, 3.66; N, 7.82. Found: C, 39.54; H, 3.54; N, 7.75.

Yttrium (III) 2,2',2'',2'''-(1,4,7,10-tetraazacyclododecane-1,4,7,10-tetrayl)tetrakis(*N*-(4-fluorobenzyl)acetamide) (YL⁷) This compound was prepared in a manner identical to YbL⁴ using L⁷ (0.045 g, 0.053 mmol) and Y(OTf)₃ (0.029 g, 0.053 mmol) dissolved in acetonitrile (5 mL) to yield a white solid (0.048 g, 65 %). ¹H NMR (400 MHz, D₂O) δ_{H} 7.40 - 7.37 (m, 8H, Ar), 7.10 (t, *J* = 8.7, 8H, Ar), 4.48 - 4.39 (m, 8H, ArCH₂), 3.25 (t, *J* = 14.3, 4H, ring NCH₂), 3.08 (d, *J* = 16.5, 4H, NCH₂CO), 2.57 (d, *J* = 14.3, 4H, ring NCH₂), 2.33 - 2.23 (m, 8H, ring NCH₂ and NCH₂CO), 2.03 (t, *J* = 14.3, 4H, ring NCH₂) NMR (376 MHz, DMSO-*d*₆) δ_{F} {¹H} (ppm) -114.9. *m/z* (ES⁺): 535.1 [M-2OTf]²⁺. HR-ESMS found *m/z* 307.10287, calculated *m/z* 307.10299 for [C₄₄H₅₂O₄N₈F₄Y]³⁺. Anal. Calcd (%) for C₄₇H₅₂YF₁₃N₈O₁₃S₃: C, 41.23; H, 3.83; N, 8.18. Found: C, 41.06; H, 3.71; N, 8.66.

2 NMR Studies





Figure S1. Bleaney plots and associated gradients for YbL¹⁻⁷-OH₂ (black) and YbL¹⁻⁷-F (red) in D₂O using crystal structures from references 6 (YbL¹⁻³) and 10 (YbL⁴⁻⁷).


Table S1. Values of $\chi_{\parallel}$ and $\chi_{\perp}$ calculated from the slopes of the Bleaney plots in Figure S1,¹¹ using an estimate of $\chi_{av}T$ as $2.50 \text{ cm}^3\text{mol}^{-1}\text{K}$ to determine χ_{av} .

	Water bound		Fluoride bound	
	$\chi_{\parallel} / \text{cm}^3\text{mol}^{-1}$	$\chi_{\perp} / \text{cm}^3\text{mol}^{-1}$	$\chi_{\parallel} / \text{cm}^3\text{mol}^{-1}$	$\chi_{\perp} / \text{cm}^3\text{mol}^{-1}$
YbL¹	0.01203	0.00657	0.00744	0.00887
YbL²	0.01226	0.00645	0.00732	0.00893
YbL³	0.01274	0.00621	0.00796	0.00860
YbL⁴	0.01246	0.00635	0.00676	0.00920
YbL⁵	0.01240	0.00638	0.00673	0.00922
YbL⁶	0.01197	0.00660	0.00638	0.00939
YbL⁷	0.01228	0.00644	0.00670	0.00923


YbL¹




YbL²




YbL³




YbL⁴



YbL⁵



YbL⁶






Figure S2. ¹H EXSY spectra (500 MHz, D₂O, 298 K) of complexes YbL¹⁻⁷ with added fluoride showing the exchange between hydrated and fluoride-bound species.




Figure S3. ^1H NMR spectra (D_2O , 298 K) of complexes EuL^{1-7} in the absence (black) and presence (red) of an excess of sodium fluoride.




Figure S4. ^1H NMR spectra (500 MHz, D_2O , 298 K) of EuL^3 at 298 K (black) and 278 K (pink).

3 Titration data

3.1 Luminescence titrations




Figure S5. Left: Changes to the EuL^1 emission spectrum on addition of sodium fluoride start of titration (black), end of titration (red), intermediate concentrations (grey). Right: Binding isotherms and fits using the intensity ratios $\Delta J = 2/\Delta J = 0$, $\Delta J = 2/\Delta J = 1$, $\Delta J = 2/\Delta J = 3$ and $\Delta J = 2/\Delta J = 4$.




Figure S6. Left: Changes to the EuL^3 emission spectrum on addition of sodium fluoride start of titration (black), end of titration (red), intermediate concentrations (grey). Right: Binding isotherms and fits using the intensity ratios.




Figure S7. Left: Changes to the EuL^4 emission spectrum on addition of sodium fluoride start of titration (black), end of titration (red), intermediate concentrations (grey). Right: Binding isotherms and fits using the intensity ratios.




Figure S8. Left: Changes to the EuL^5 emission spectrum on addition of sodium fluoride start of titration (black), end of titration (red), intermediate concentrations

(grey). Right: Binding isotherms and fits using Binding isotherms and fits using the intensity ratios.




Figure S9. Left: Changes to the EuL^6 emission spectrum on addition of sodium fluoride start of titration (black), end of titration (red), intermediate concentrations (grey). Right: Binding isotherms and fits using Binding isotherms and fits using the intensity ratios.




Figure S10. Left: Changes to the EuL^7 emission spectrum on addition of sodium fluoride start of titration (black), end of titration (red), intermediate concentrations (grey). Right: Binding isotherms and fits using the Binding isotherms and fits using the intensity ratios.

3.2 NMR titrations




Figure S11. Binding isotherms and fits for titration of EuL^1 with NaF monitoring ^1H NMR integrals relative to DSS at 298 K.




Figure S12. Binding isotherms and fits for titration of EuL^3 with NaF monitoring ^1H NMR integrals relative to DMF and ^{19}F NMR integrals relative to OTf at 278 K.




Figure S13. Binding isotherms and fits for titration of EuL^4 with NaF monitoring ^1H NMR integrals relative to DSS at 298 K.




Figure S14. Binding isotherms and fits for titration of EuL^5 with NaF monitoring ^1H NMR integrals relative to DSS at 298 K.




Figure S15. Binding isotherms and fits for titration of EuL^6 with NaF monitoring ^1H NMR integrals relative to DSS at 298 K.




Figure S16. Binding isotherms and fits for titration of EuL^7 with NaF monitoring ^{19}F NMR integrals of the ligand fluorines relative to OTf at 298 K.

4 $\ln K$ vs. D_1




Figure S17. Correlation between $\ln K$ (measured by luminescence) of the Eu complexes of L^{1-7} and D_1 values for the Yb complexes from 1H Bleaney plots.

5 Rates of Exchange

5.1 LuL^x 1H NMR spectra




Figure S18. 1H NMR spectra (D_2O , 298 K) of LuL^1 upon addition of increasing amounts of sodium fluoride.




Figure S19. ^1H NMR spectra (D_2O , 298 K) of LuL^3 upon addition of increasing amounts of sodium fluoride.




Figure S20. ^1H NMR spectra (D_2O , 298 K) of LuL^4 upon addition of increasing amounts of sodium fluoride.




Figure S21. ^1H NMR spectra (D_2O , 298 K) of LuL^4 (bottom) with added sodium fluoride at 298 K (red) and 323 K (black).

5.2 $^1\text{H}/^{19}\text{F}$ Inversion recovery data




Figure S22. ^1H intensities of the methyl groups of $\text{YbL}^2\text{-OH}_2$ and $\text{YbL}^2\text{-F}$ following selective inversion (top) and non-selective inversion (bottom) at 278 K, fits are shown in red.




Figure S23. ^1H intensities of the methyl groups of $\text{YbL}^2\text{-OH}_2$ and $\text{YbL}^2\text{-F}$ following selective inversion (top) and non-selective inversion (bottom) at 283 K, fits are shown in red.




Figure S24. ^1H intensities of the methyl groups of $\text{YbL}^2\text{-OH}_2$ and $\text{YbL}^2\text{-F}$ following selective inversion (top) and non-selective inversion (bottom) at 288 K, fits are shown in red.




Figure S25. ^1H intensities of the methyl groups of $\text{YbL}^2\text{-OH}_2$ and $\text{YbL}^2\text{-F}$ following selective inversion (top) and non-selective inversion (bottom) at 293 K, fits are shown in red.




Figure S26. ^1H intensities of the methyl groups of $\text{YbL}^2\text{-OH}_2$ and $\text{YbL}^2\text{-F}^-$ following selective inversion (top) and non-selective inversion (bottom) at 298 K, fits are shown in red.




Figure S27. ^1H intensities of the methyl groups of $\text{YbL}^2\text{-OH}_2$ and $\text{YbL}^2\text{-F}^-$ following selective inversion (top) and non-selective inversion (bottom) at 303 K, fits are shown in red.




Figure S28. ^{19}F intensities of the ligand benzyl substituent of $\text{YbL}^7\text{-OH}_2$ and $\text{YbL}^7\text{-F}$ following selective inversion (top) and non-selective inversion (bottom) at 278 K, fits are shown in red.




Figure S29. ^{19}F intensities of the ligand benzyl substituent of $\text{YbL}^7\text{-OH}_2$ and $\text{YbL}^7\text{-F}$ following selective inversion (top) and non-selective inversion (bottom) at 283 K, fits are shown in red.




Figure S30. ^{19}F intensities of the ligand benzyl substituent of $\text{YbL}^7\text{-OH}_2$ and $\text{YbL}^7\text{-F}$ following selective inversion (top) and non-selective inversion (bottom) at 288 K, fits are shown in red.




Figure S31. ^{19}F intensities of the ligand benzyl substituent of $\text{YbL}^7\text{-OH}_2$ and $\text{YbL}^7\text{-F}$ following selective inversion (top) and non-selective inversion (bottom) at 293 K, fits are shown in red.




Figure S32. ^{19}F intensities of the ligand benzyl substituent of $\text{YbL}^7\text{-OH}_2$ and $\text{YbL}^7\text{-F}$ following selective inversion (top) and non-selective inversion (bottom) at 298 K, fits are shown in red.




Figure S33. ^{19}F intensities of the ligand benzyl substituent of $\text{YbL}^7\text{-OH}_2$ and $\text{YbL}^7\text{-F}$ following selective inversion (top) and non-selective inversion (bottom) at 303 K, fits are shown in red.

Table S2. Rates of exchange at multiple temperatures measured using selective inversion and fit using CIFIT¹² for YbL² and YbL⁷ with fluoride in D₂O at 500 MHz.

YbL ²		YbL ⁷	
Temperature (K)	k (s ⁻¹)	Temperature (K)	k (s ⁻¹)
278	50.0 ± 1.0	278	14.8 ± 0.3
283	71.0 ± 1.1	283	22.7 ± 1.0
288	108.3 ± 1.6	288	31.5 ± 1.0
293	160.7 ± 4.0	293	42.8 ± 2.0
298	215.7 ± 3.0	298	61.2 ± 3.6
303	283.1 ± 6.0	303	84.2 ± 7.8

¹ E. Hernandez-Nunez, H. Tlahuext, R. Moo-Puc, H. Torres-Gomez, R. Reyes-Martinez, R. Cedillo-Rivera, C. Nava-Zuazo, and G. Navarrete-Vazquez, *Eur. J. Med. Chem.*, 2009, **44**, 2975–2984.

² R. Ferraccioli and A. Forni, *Eur. J. Org. Chem.*, 2009, **2009**, 3161–3166.

³ G. Zucchi, R. Scopelliti, and J.-C. G. Bünzli, *J. Chem. Soc., Dalton Trans.*, 2001, 1975–1985.

⁴ T. Huynh, C. Valant, I. T. Crosby, P. M. Sexton, A. Christopoulos, and B. Capuano, *J. Med. Chem.*, 2013, **56**, 8196–8200.

⁵ H. Maumela, R. D. Hancock, L. Carlton, J. H. Reibenspies, and K. P. Wainwright, *J. Am. Chem. Soc.*, 1995, **117**, 6698–6707.

⁶ S. Aime, A. Barge, J. I. Bruce, M. Botta, J. A. K. Howard, J. M. Moloney, D. Parker, A. S. de Sousa, and M. Woods, *J. Am. Chem. Soc.*, 1999, **121**, 5762–5771.

⁷ R. Katakya, K. E. Matthes, P. E. Nicholson, D. Parker, and H.-J. Buschmann, *J. Chem. Soc., Perkin Trans. 2*, 1990, 1425.

⁸ G. Zucchi, R. Scopelliti, P.-A. Pittet, J.-C. G. Bünzli, and R. D. Rogers, *J. Chem. Soc., Dalton Trans.*, 1999, 931–938.

⁹ P. Kuzmic, *Anal. Biochem.*, 1996, **237**, 260–273.

¹⁰ R. S. Dickins, J. A. K. Howard, C. W. Lehmann, J. Moloney, D. Parker, and R. D. Peacock, *Angew. Chem. Int. Ed.*, 1997, **36**, 521–523.

¹¹ From equations 2 and 3 in the main paper, it should be clear that

$$\delta_{PC} = D_1 \frac{(3\cos^2\theta - 1)}{r^3} = \frac{1}{2N_A} \left[\frac{(3\cos^2\theta - 1)}{r^3} (\chi_{\parallel} - \chi_{av}) \right]$$

so,

$$D_1 = \frac{1}{2N_A} [(\chi_{\parallel} - \chi_{av})]$$

¹² A. D. Bain and J. Cramer, *Journal of Magnetic Resonance, Series A*, 1996, **118**, 21–27.